文献速递眼底病与葡萄膜炎

大型美国索赔数据库中非感染性葡萄膜炎患者免疫抑制药物与冠状病毒病2019结局的关联

Association between Immunosuppressive Drugs and Coronavirus Disease 2019 Outcomes in Patients with Noninfectious Uveitis in a Large US Claims Database.
PubMed 文献 · Ophthalmology · 2022-05-17

这项回顾性队列研究利用美国全国去标识索赔数据库,纳入52 286例非感染性葡萄膜炎患者,评估2020年1月20日至12月31日(COVID-19疫苗广泛接种前)免疫抑制治疗与COVID-19感染、住院及院内死亡的风险。调整模型显示,全身性糖皮质激素暴露与感染(HR 2.66)和住院(HR 3.26)风险升高相关,院内死亡风险未达统计学显著(HR 1.99,95%CI 0.93-4.27,P=0.08);TNF-α抑制剂与感染风险升高相关(HR 1.48),其他免疫抑制治疗未增加风险。

要点

  • 全身性糖皮质激素暴露与COVID-19感染风险升高相关(HR 2.66)。
  • 全身性糖皮质激素暴露与COVID-19住院风险升高相关(HR 3.26)。
  • TNF-α抑制剂与感染风险升高相关(HR 1.48),其他免疫抑制治疗未增加风险。

核心结论

  • 在COVID-19疫苗广泛接种前,门诊全身性糖皮质激素暴露与非感染性葡萄膜炎患者COVID-19感染和严重结局风险升高相关。
  • 未来研究应评估已接种疫苗的非感染性葡萄膜炎患者中免疫抑制的影响。
  • 限制全身性糖皮质激素暴露和使用替代疗法可能是必要的。

研究设计与样本

  • 回顾性队列研究,使用Optum Labs数据仓库这一美国全国去标识索赔数据库,研究时间为2020年1月20日至2020年12月31日(COVID-19疫苗广泛接种前)。
  • 纳入自2017年1月1日起至少有一次非感染性葡萄膜炎诊断的患者,共52 286例,其中12 000例(23.0%)在风险期内暴露于免疫抑制药物。
  • 采用Cox比例风险模型估计各变量与COVID-19结局的未调整和调整风险比(HR),免疫抑制药物暴露使用时间更新的二分类指标。
  • 为评估全身性糖皮质激素的剂量依赖效应,调整模型中将暴露期间泼尼松平均日剂量作为连续变量纳入。

主要发现

  • 调整模型中,全身性糖皮质激素暴露与COVID-19感染风险升高相关(HR 2.66;95%CI 2.19-3.24;P<0.001)。
  • 调整模型中,全身性糖皮质激素暴露与COVID-19住院风险升高相关(HR 3.26;95%CI 2.46-4.33;P<0.001)。
  • 调整模型中,全身性糖皮质激素暴露与COVID-19院内死亡风险无显著关联(HR 1.99;95%CI 0.93-4.27;P=0.08)。
  • 全身性糖皮质激素剂量递增与上述结局风险增加相关。
  • TNF-α抑制剂与COVID-19感染风险升高相关(HR 1.48;95%CI 1.08-2.04;P=0.02),其他免疫抑制治疗未增加感染、住院或死亡风险。

临床怎么用

  • 原文结论指出,限制全身性糖皮质激素暴露和使用替代疗法可能是必要的。
  • 原文结论指出,未来研究应评估已接种疫苗的非感染性葡萄膜炎患者中免疫抑制的影响。

局限性

  • 研究时期为COVID-19疫苗广泛接种前,结论可能不适用于疫苗接种后的情况。
  • 原文结论指出未来研究应评估已接种疫苗的非感染性葡萄膜炎患者中免疫抑制的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the dose-dependent risk of systemic corticosteroids (SCs) and the risk of other immunosuppressive therapies on coronavirus disease 2019 (COVID-19) infection, hospitalization, and death in patients with noninfectious uveitis (NIU). DESIGN: A retrospective cohort study from January 20, 2020, to December 31, 2020 (an era before widespread COVID-19 vaccination), using the Optum Labs Data Warehouse, a US national de-identified claims database. PARTICIPANTS: Patients who had at least 1 NIU diagnosis from January 1, 2017. METHODS: Unadjusted and adjusted hazard ratios (HRs) were estimated for each variable and COVID-19 outcome using Cox proportional hazards models, with time-updated dichotomous indicators for outpatient immunosuppressive medication exposure. To assess the dose-dependent effect of SC exposure, the average daily dose of prednisone over the exposed interval was included in the adjusted models as a continuous variable, in addition to the dichotomous variable. MAIN OUTCOME MEASURES: Incidence rates of COVID-19 infection, COVID-19-related hospitalization, and COVID-19-related in-hospital death. RESULTS: This study included 52 286 NIU patients of whom 12 000 (23.0%) were exposed to immunosuppressive medications during the risk period. In adjusted models, exposure to SCs was associated with increased risk of COVID-19 infection (HR, 2.66; 95% confidence interval [CI], 2.19-3.24; P < 0.001), hospitalization (HR, 3.26; 95% CI, 2.46-4.33; P < 0.001), and in-hospital death (HR, 1.99; 95% CI, 0.93-4.27; P = 0.08). Furthermore, incremental increases in the dosage of SCs were associated with a greater risk for these outcomes. Although tumor necrosis factor-α (TNF-α) inhibitors were associated with an increased risk of infection (HR, 1.48; 95% CI, 1.08-2.04; P = 0.02), other immunosuppressive treatments did not increase the risk of COVID-19 infection, hospitalization, or death. CONCLUSIONS: This study from an era before widespread COVID-19 vaccination demonstrates that outpatient SC exposure is associated with greater risk of COVID-19 infection and severe outcomes in patients with NIU. Future studies should evaluate the impact of immunosuppression in vaccinated NIU patients. Limiting exposure to SCs and use of alternative therapies may be warranted.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Sun Y, Miller DC, Akpandak I, et al. Association between Immunosuppressive Drugs and Coronavirus Disease 2019 Outcomes in Patients with Noninfectious Uveitis in a Large US Claims Database. Ophthalmology. 2022. PMID: 35588945. doi:10.1016/j.ophtha.2022.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。